Developing
The World’s First Treatment Planning Solution
Our innovative technology enables precise and accurate absorbed dose calculation, distribution and risk assessment for radiopharmaceuticals.
Partnering with Korea’s key institutes
Gearing up to
Revolutionize Cancer Treatment Planning Worldwide
Founded in 2020, the Company has since assembled experts in the fields of medicine, artificial intelligence, and radiology and core technology utilizes PET-SPECT/CT images and applies a combination of innovative artificial intelligence and micro-dosimetry calculations to guide doctors in formulating treatment plans with radiopharmaceutical agents.
10%
↓
5%
Reduce Error by Using Patient Image
70%
↓
95%
Increased Accuracy in Dose Calculation
5 min
↓
1 min
Increased Calculation Speed through AI
β emiiters
↓
β + α emitters
Precise dose calculation with RBE
As an essential tool for both patients and doctors, raymed’s software will significantly improve the patient’s chances of survival through enabling precise therapy.
Selected for
The Korean IP-R&D support project
RayMed has been selected for the IP-R&D strategy support project led by the Korean Intellectual Property Strategy Development Institute. We have completed the filing of relevant domestic patents and we are now looking to submit international patents in the United States and Europe through the PCT in the latter half of 2025.
Product and Technology
RayVision™, by raymed, provides accurate assessment of absorbed dose in patients undergoing radiopharmaceutical treatment and tailors treatment plans to each individual patient.
Our model
Revolutionizing Radiopharmaceutical Treatment: Tailored Dosing with RayVision™
- Medical Software Development and Supply
– Development and provision of medical diagnostic support software, including graphic, image, and video processing software, as well as data management and maintenance consulting.
(Scheduled for supply from 2025) - Radiation Therapy and Dosimetry Technology
– Comprehensive distribution services for radiation therapy planning software, dosimetry equipment, and radiation devices, covering wholesale, retail, rental, and brokerage.
(Scheduled for supply from 2025) - Medical Imaging and Diagnostic Devices
– Integrated services for diagnostic imaging equipment and specialized medical devices, including remote monitoring, technical maintenance, and rental. (Scheduled for supply from 2026) - Medical Data Analysis and Information Provision
– Providing medical analysis, remote diagnostic support services, and cancer prevention / disease diagnosis information
(scheduled for distribution from 2025) - Radiopharmaceutical Distribution and Clinical Services
– Comprehensive distribution, retail, wholesale, and brokerage of radiopharmaceuticals, along with clinical services supported by treatment planning software. (Scheduled for supply from 2027)
How it works
Using Image Data for Precise Treatment with RayVision™
RayVision™ analyzes patient image data transmitted through the hospital’s internal Picture Archiving and Communication System (PACS) to visualize predicted biodistribution and to assess precise absorbed dose which can aid medical professionals to establish precise treatment plans.
Efficiency
Rapid Dose Calculation: AI's Impact on Treatment Speed
Conventional Monte Carlo-based techniques require at least two to four weeks to calculate radiation dose. However, the use of artificial intelligence can significantly accelerate this process, allowing crucial dosimetry measurements to be made within a minute; thus, greatly enhancing the effectiveness and cost efficiency of radiopharmaceutical treatment for patients.
Patient images
Personalized
Patient images
Patient images
More ACCURATE dosimetry
Precise 3D biodistribution + prediction of patient survival
ACCELERATED AI based calculation
CEO Insights
RayMed's Vision and Innovation
Milestones and Achievements
Establishment of a research facility within the National Radioisotope Drug Development center in Korea
Selected for the 3rd Osong Bio Nesting Project by Korean Government
Designated as a family company of the Korea Atomic Energy Research Institute (KAERI)
Selected for the Small and Medium-sized Enterprise (SME) Technology Innovation Development Support Program (TIPS) by Korean Government
Establishment of a medical advisory team from key domestic general hospitals in Korea
Funding: Approx. 4 mil USD (venture capital funds and government grants)
- 현재 4개의 방사성의약품 파이프라인을 보유하고 있으며 이 중 3개는 신약개발사와 협업으로 진행 중.
- [Ray-002]는 기존 약물의 타겟팅 물질에 대한 IND 승인이 완료 된 물질을 가지고 방사성의약품으로 전환 중이며, [Ray-004]는 표적물질부터 킬레이터, 링커의 구조까지 방사성의약품을 개발을 전제로 하여 협력기관과의 공동개발 형태로 진행되고 있음.
- 기존 신약개발사들이 80% 이상 개발 완료한 검증된 타겟팅 물질들을 RPT로 전환하여 개발하는 플랫폼 비즈니스 방식으로,
여러 이질적 회사들의 후보물질을 포트폴리오화 함으로써 단일 회사 대비 더 높은 성공가능성을 확보하고 있음.
About our company
We are experts in the fields of medicine, artificial intelligence, and radiology
Grayson Kim
CEO
- PwC Senior Partner (Korea/US/Tokyo) – 30 yrs
- HLB Life Science
- M.S., Integrative Medicine, Yonsei University College of Medicine
- B.S., Business Administration, Yonsei University
Mr. Grayson Kim has majored in Business administration at Yonsei University and completed his Master’s in Integrated medicine. With 32 years of experience at PwC, he possess a diverse international business experience and world wide networks from locations such as the US, Tokyo, and China. In addition, he is familiar with oversesas listings, M&A, fundraising, and various other aspects of business consulting and operations. He also has served as a standing auditor for the HLB Group, bringing experience and networks related to global pharmaceutical companies.
Wonmo Sung
CSO
- Harvard Medical School / MGH, Research Fellow TOPAS-nBIO developer
- Ph.D., Radiation Convergence Medical Life Science, Seoul National University
- M.S., Radiological physics, Seoul National University
Professor Won Mo Sung completed his Ph.D. at Seoul National University, and has previously held a postdoctoral position at Harvard Medical School, where he played a key role in developing the external beam radiation treatment planning system software, TOPAS-nBIO. As one of its core developers, he is now developing an ultra-precise radiation treatment planning software (RayVision™) utilizing the company’s core technology of micro-dosimetry.
Kyung Oh Jung
CTO
- Stanford University / Postdoctoral Fellow
- M.S. / Ph.D., Nuclear medicine, Seoul National University
- B.S., Bioengineering, Korea University
Professor Kyung Oh Jung completed his Ph.D. at Seoul National University in nuclear medicine, and was previously a postdoctoral fellow at Stanford University, where he pursued research in the development of molecular tools for cellular tracking by positron emission tomography. Through his expertise, he is now aiding in the fine-tuning of RayVision™ through incorporation of clinically relevant biological variables.
Hyejin Kim
CRO
- Ph.D., Applied Biotechnology, Seoul National University
- M.S., Radiation Convergence Biomedical Life, Seoul National University
Dr. Hyejin Kim earned her Ph.D. from Seoul National University in applied biotechnology and has extensive experience in leveraging cutting-edge micro-dosimetry technology.
Hyunbin Lee
SR
- Pharm D., Northeastern University
- Biogen Inc.
Mr. Hyubin Lee possesses a wealth of knowledge regarding compliance and understanding of global regulatory affairs in the pharmaceutical landscape.
Jiho Rhim
SR
- M.S., Cancer biology, National Cancer Center GCSP
- B.S., Biochemistry King’s College London
Mr. Jiho Rhim, with a background in cancer biology, is highly experienced in the laboratory work and oncology-related studies.
